TP53 and neoplasm: Overall, TP53 mutations in serum derived cfDNA at diagnosis were significantly more observed in patients with FIGO stage IV disease (p = 0.024; Table 4) but not related to other parameters including cfDNA yields or tumor tissue TP53 mutation frequencies (Table 4).